Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapor product

Regulatory Toxicology and Pharmacology

Volumn 87, Issue , 2017, Pages 30-35

  Yuki, Dai ^a   Sakaguchi, Chikako ^a   Kikuchi, Akira ^a   Futamura, Yasuyuki ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Clinical study; Japanese healthy adult male smokers; Mouth level exposure; Nicotine; Pharmacokinetics; Prototype novel tobacco vapor product; Relative bioavailability

Indexed keywords

NICOTINE; NICOTINIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CONVENTIONAL CIGARETTE; GENERAL DEVICE; HUMAN; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH LEVEL EXPOSURE; OUTCOME ASSESSMENT; PHYSICAL PARAMETERS; PROTOTYPE NOVEL TOBACCO VAPOR PRODUCT; SMOKING; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CROSSOVER PROCEDURE; ELECTRONIC CIGARETTE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TOBACCO;

CROSS-OVER STUDIES; ELECTRONIC NICOTINE DELIVERY SYSTEMS; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; SMOKING; TOBACCO;

EID: 85018723206     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2017.05.005     Document Type: Article

References (30)

1. Benowitz, N.L., Porchet, H., Sheiner, L., Jacob, P. 3rd, Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther. 44 (1988), 23–28.
2. Bergström, M., Nordberg, A., Lunell, E., Antoni, G., Långström, B., Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin. Pharmacol. Ther. 57 (1995), 309–317.
3. Dempsey, D., Tutka, P., Jacob, P. 3rd, Allen, F., Schoedel, K., Tyndale, R.F., Benowitz, N.L., Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76 (2004), 64–72.
4. Digard, H., Proctor, C., Kulasekaran, A., Malmqvist, U., Richter, A., Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob. Res. 15 (2013), 255–261.
5. Farsalinos, K.E., Spyrou, A., Stefopoulos, C., Tsimopoulou, K., Kourkoveli, P., Tsiapras, D., Kyrzopoulos, S., Poulas, K., Voudris, V., Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). Sci. Rep., 17, 2015, 11269.
6. Foulds, J., Ramstrom, L., Burke, M., Fagerström, K., Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob. Control 12 (2003), 349–359.
7. Frost-Pineda, K., Zedler, B.K., Oliveri, D., Feng, S., Liang, Q., Roethig, H.J., Shortterm clinical exposure evaluation of a third-generation electrically heated cigarette smoking system (EHCSS) in adult smokers. Regul. Toxicol. Pharmacol. 52 (2008), 104–110.
8. Haziza, C., de La Bourdonnaye, G., Merlet, S., Benzimra, M., Ancerewicz, J., Donelli, A., Baker, G., Picavet, P., Lüdicke, F., Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: a randomized controlled study in confinement. Regul. Toxicol. Pharmacol. 29 (2016), 489–499.
9. Health Canada, Official Method T-115. Determination of ‘‘Tar’’, Nicotine and Carbon Monoxide in Mainstream Tobacco Smoke. 1999.
10. Hukkanen, J., Jacob, P. 3rd., Benowitz, N.L., Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57 (2005), 79–115.
11. ISO 3308, Routine Analytical Cigarette-smoking Machine - Definitions and Standard Conditions. 2000.
12. Lüdicke, F., Baker, G., Magnette, J., Picavet, P., Weitkunat, R., Reduced exposure to harmful and potentially harmful smoke constituents with the tobacco heating system 2.1. Nicotine Tob. Res., 1, 2016 pii: ntw164.
13. Lunell, E., Molander, L., Ekberg, K., Wahren, J., Site of nicotine absorption from a vapour inhaler–comparison with cigarette smoking. Eur. J. Clin. Pharmacol. 55 (2000), 737–741.
14. Marsot, A., Simon, N., Nicotine and cotinine levels with electronic cigarette: a review. Int. J. Toxicol. 35 (2016), 179–185.
15. Ministry of Health, Labour and Welfare, Japan, Guideline for Bioequivalence Studies of Generic Products. (Attachment 1 of Division-Notification 0229 No. 10 of the Pharmaceutical and food Safety Bureau), 2012.
16. Miura, N., Yuki, D., Minami, N., Kakehi, A., Onozawa, M., Pharmacokinetic analysis of nicotine when using non-combustion inhaler type of tobacco product in Japanese adult male smokers. Regul. Toxicol. Pharmacol. 67 (2013), 198–205.
17. Mooney, M.E., Li, Z.Z., Murphy, S.E., Pentel, P.R., Le, C., Hatsukami, D.K., Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol. Biomark. Prev. 17 (2008), 1396–1400.
18. Russell, M.A., Feyerabend, C., Cole, P.V., Plasma nicotine levels after cigarette smoking and chewing nicotine gum. Br. Med. J. 1 (1976), 1043–1046.
19. Russell, M.A., Jarvis, M.J., Sutherland, G., Feyerabend, C., Nicotine replacement in smoking cessation. Absorption of nicotine vapor from smoke-free cigarettes. JAMA 257 (1987), 3262–3265.
20. Sakaguchi, C., Kakehi, A., Minami, N., Kikuchi, A., Futamura, Y., Exposure evaluation of adult male Japanese smokers switched to a heated cigarette in a controlled clinical setting. Regul. Toxicol. Pharmacol. 69 (2014), 338–347.
21. Scherer, G., Smoking behaviour and compensation: a review of the literature. Psychopharmacol. (Berl.) 145 (1999), 1–20.
22. Shepperd, C.J., StCharles, F.K., Lien, M., Dixon, M., Validation of methods for determining consumer smoked cigarette yields from cigarette filter analysis. Beitr. zur Tab. Int. 22 (2006), 176–184.
23. Shepperd, C.J., Eldridge, A.C., Mariner, D.C., McEwan, M., Errington, G., Dixon, M., A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure. Regul. Toxicol. Pharmacol. 55 (2009), 97–109.
24. Sobue, S., Sekiguchi, K., Kikkawa, H., Akasaki, M., Irie, S., Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking. Biol. Pharm. Bull. 29 (2006), 1068–1073.
25. Swan, G.E., Lessov-Schlaggar, C.N., Bergen, A.W., He, Y., Tyndale, R.F., Benowitz, N.L., Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet. Genom. 19 (2009), 388–398.
26. Trtchounian, A., Williams, M., Talbot, P., Conventional and electronic cigarettes (e-cigarettes) have different smoking characteristics. Nicotine Tob. Res. 12 (2010), 905–912.
27. Walele, T., Sharma, G., Savioz, R., Martin, C., Williams, J., A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. Regul. Toxicol. Pharmacol. 74 (2016), 187–192.
28. Watson, C., McCraw, J., Polzin, G., Ashley, D., Barr, D., Development of a method to assess cigarette smoke intake. Environ. Sci. Technol. 38 (2004), 248–253.
29. Yuki, D., Kikuchi, A., Miura, N., Kakehi, A., Onozawa, M., Good relationship between saliva cotinine kinetics and plasma cotinine kinetics after smoking one cigarette. Regul. Toxicol. Pharmacol. 67 (2013), 240–245.
30. Yun, H.Y., Seo, J.W., Choi, J.E., Baek, I.H., Kang, W., Kwon, K.I., Effects of smoking on the pharmacokinetics and pharmacodynamics of a nicotine patch. Biopharm. Drug Dispos. 29 (2008), 521–528.